Next generation sequencing and the molecular tumor board from the point of view of oncologists.

Abstract

Molecular genetic methods have evolved dramatically in the last decade. In particular, sequencing of the new generation - NGS has become a financially and technically available examination. Thus, it begins to be used in the clinical practice of many specializations, including oncology. The proper use of these methods is a way to personalized oncology - treatment of the patient based on the occurrence of specific genetic aberrations, which are confirmed in his cancer, regardless of the histopathological type of tumor. This principle is completely new in oncology and raises number of questions and problems. The interpretation of the results of molecular genetic examinations is very complex and demanding, and therefore new multidisciplinary teams, so-called molecular tumor boards, are being created. The worldwide standardization of these boards is currently underway. Recommendations regarding the indication of NGS examinations in oncology patients are also being set.At the European level in the form of ESMO recommendations and at the national level also. Personalized oncology is the future of this field, which will lead to the best treatment response and minimize side effects.